Asceneuron’s R&D pipeline is composed of innovative small molecules designed to prevent progression and provide symptomatic relief of neurodegenerative diseases.

Asceneuron aims to address high unmet medical needs in neurodegenerative diseases such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. Our pipeline is composed of innovative small-molecule therapeutics aiming to prevent disease progression in tauopathies and reverse cognitive impairment in dementia.

 

pipeline.jpg

TAUOPATHIES

O-GLCNACASE INHIBITORS

PSP*
FTD*
AD*

COGNITIVE DYSFUNCTION IN DEMENTIA

M1 PAM

PDD*
LBD*
AD*

AD: Alzheimer's disease
LBD: Lewy Body Dementia

FTD: Frontotemporal dementia
PDD: Parkinson's disease dementia
PSP: Progressive Supranuclear Palsy